# Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

> **NCT04361708** · PHASE1 · RECRUITING · sponsor: **University of Chicago** · enrollment: 54 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT04361708
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-08
- **Primary completion:** 2026-06
- **Final completion:** 2027-05
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361708, "Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04361708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*